[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483068":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":50,"collaborators":18,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":18,"enrollmentInfo":62,"targetDuration":18,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Peter MacCallum Cancer Centre, Australia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"[U-13C]Glucose Infusion","EXPERIMENTAL","A 13.3% solution of sterile, pyrogen-free \\[U-13C\\]glucose in sterile water will be infused intravenously rapidly over 10 minutes to a total dose of 8 grams (bolus dose). Then the infusion will change to a rate of 4 grams\u002F hour. The infusion will continue until the time of tumour excision or biopsy, planned 2-3 hours.",[13],"Other: [U-13C]Glucose Infusion",{"label":15,"type":16,"description":17,"interventionNames":18},"No [U-13C]Glucose Infusion","NO_INTERVENTION","Blood and tissue samples to be collected for translational research studies, no other additional intervention.",null,[20],{"type":6,"name":9,"description":21,"armGroupLabels":22,"otherNames":18},"Peri-operative infusion of \\[U-13C\\]glucose",[9],[24],{"name":25,"affiliation":5,"role":26},"Aparna Rao, MBBS PhD","PRINCIPAL_INVESTIGATOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":18,"email":32},"Aparna Rao","CONTACT","+61385595000","aparna.rao@petermac.org",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Peter Mac Callum Cancer Centre","RECRUITING","Melbourne","Victoria","3002","Australia","AU",{"type":43,"coordinates":44},"Point",[45,46],144.96332,-37.814,{"lat":46,"lon":45},[49],{"name":29,"role":30,"phone":18,"phoneExt":18,"email":32},{"type":51,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100483068","metabolic-phenotypes-in-melanoma-100483068",false,"NCT05570227","Metabolic Phenotypes in Melanoma","Identification of Metabolic Phenotypes Associated With Prognosis and Therapeutic Response in Patients With Melanoma","MetaMel","Inclusion Criteria:\n\n1. Patient has provided written informed consent\n2. Male or female aged 18 years or older at written informed consent\n3. Presence of a known melanoma lesion requiring surgical excision or biopsy\n4. Patient is willing and able to comply with the protocol for the duration of the study including undergoing biopsies and receiving a stable isotope infusion (where applicable)\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will be excluded from receiving a \\[U-13C\\]Glucose infusion:\n\n1. Diabetes mellitus\n2. Pregnancy or breast feeding\n3. Patients unable to comply with study procedures and follow up in the opinion of the investigator","ALL","18 Years",{"count":63,"type":64},240,"ESTIMATED","INTERVENTIONAL",[67],"NA","This is a single centre, correlative, longitudinal, biomarker study that aims to describe the metabolic features of human melanoma using mass spectrometry.",[70],"Melanoma",[72],"Metabolism","2023-07-03",{"date":75,"type":76},"2023-07-06","ACTUAL",{"date":78,"type":76},"2023-06-27",{"date":80,"type":64},"2027-10",{"name":5,"class":6},1]